

ECZACIBAŞI YATIRIM HOLDİNG ORTAKLIĞI A.Ş. Shares Transaction Notification

Summary

Notice of Share Purchases of EİS Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar Sanayi ve Ticaret A.Ş.

Shares Transaction Notification

Related Companies [ECILC]

Related Funds []

Shares Transaction Notification	
Update Notification Flag	Hayır (No)
Correction Notification Flag	Hayır (No)
Date Of The Previous Notification About The Same Subject	-
Postponed Notification Flag	Hayır (No)
Explanations	

On 04.03.2022, our company has purchased TRY 261,959 nominal value shares of EİS Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar Sanayi ve Ticaret A.Ş. (ECILC) with a price range of TRY 7.87 to 8.03. With this transaction, our share in the capital of EİS Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar Sanayi ve Ticaret A.Ş. has become 30.46% as of 04.03.2022.

Detailed information on the purchase transaction is given in the table below.

This statement has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this disclosure statement, the Turkish version shall prevail.

Shares Transaction Information

Transaction Date	Total Nominal Value Of Shares Purchased (TRY)	Total Nominal Value Of Shares Sold (TRY)	Net Nominal Value Of Transactions (TRY)	Nominal Value of Shares Owned At The Beginning Of Day (TL)	Nominal Value of Shares Owned At The End Of Day (TL)	Ratio of Shares Owned At The Beginning Of Day (%)	Ratio of Voting Rights Owned At The Beginning Of Day (%)	Ratio of Shares Owned At The End Of Day (%)	Ratio of Voting Rights Owned At The End Of Day (%)
04/03/2022	261.959	0	261.959	208.497.255,39	208.759.214,39	% 30,43	% 30,43	% 30,46	% 30,46

We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.